NCT02071381
Completed
Phase 1
A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects
Overview
- Phase
- Phase 1
- Intervention
- DW330SR 45mg
- Conditions
- Healthy
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Locations
- 1
- Primary Endpoint
- Trans-OH as Main Metabolites of DW330SR, DW330SR, Cmax, AUClast of DW1030
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this study is to evaluate drugs interactions to compare pharmacokinetics in groups of monotherapy DW330SR, monotherapy DW1030, and coadministration DW330SR and DW1030
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy Adult males aged 20\~40 years at screening visit
- •Subjects with range of 19 kg/m2 \~ 27 kg/m2 as BMI measurements at screening visit
- •Subjects with BP range of below:
- •90 mmHg ≤ Systolic BP ≤ 140 mmHg 50 mmHg ≤ Diastolic BP ≤ 90mmHg
- •Subjects who voluntarily agreed with written consent that be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the reguirement of the study
Exclusion Criteria
- •Subjects with clinically significant disease or history such as Liver, kidney, gastrointestinal, respiratory, musculoskeletal, endocrine, nervous psychiatric, blood tumor system and cardiovascular. (In particular, bronchial asthma, severe hepatic, renal failure, severe blood disorders, severe myasthenia gravis, cardiac dysfunction, peptic ulcer, etc.)
- •Subjects with history of gastrointestinal disease (ex, Chrones dz, peptic ulcer, etc) affect the absorption of Investigational drugs or history of surgery (except for a simple appendectomy or hernia surgery)
- •Subjects with hypersensitivity reaction or clinically significant disease in drugs (Aspirin, NSAID and antibiotics) including ingredient of DW330SR and DW1030 and Food
Arms & Interventions
A
only DW330SR 45mg
Intervention: DW330SR 45mg
B
only DW1030 75mg
Intervention: DW1030 75mg
C
DW330SR 45mg and DW1030 75mg
Intervention: DW330SR 45mg
C
DW330SR 45mg and DW1030 75mg
Intervention: DW1030 75mg
Outcomes
Primary Outcomes
Trans-OH as Main Metabolites of DW330SR, DW330SR, Cmax, AUClast of DW1030
Time Frame: -28 ~ -2day(screening), -1day, 1day, 2day
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male AdultsHealthyNCT04343547Daewoong Pharmaceutical Co. LTD.34
Completed
Not Applicable
Study to Evaluate a Pharmacokinetic Drug Interaction Between Eperisone Hydrochloride and Aceclofenac in Healthy Male SubjectsAcute Low Back PainNCT01638286Hanmi Pharmaceutical Company Limited24
Completed
Phase 1
A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult SubjectsHypertensionHyperlipidemia (E.G., Hypercholesterolemia)NCT05460364Boryung Pharmaceutical Co., Ltd36
Active, not recruiting
Phase 1
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-BHypertensionNCT06618079Huons Co., Ltd.46
Completed
Phase 1
Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.Healthy VolunteersNCT05625334Vectura, Inc.86